viral
pathogenesi
field
rapid
evolut
reflect
dynam
develop
system
biolog
continu
introduct
new
improv
methodolog
therefor
final
chapter
dedic
futur
look
lie
ahead
field
recruit
number
scientist
write
short
piec
free
specul
futur
develop
respect
area
expertis
decad
detail
biolog
studi
taught
us
host
defens
viral
infect
spread
reli
multipl
compon
immun
system
rang
parenchym
cell
product
interferon
innat
immun
respons
myeloid
lymphoid
cell
lymphocytedepend
cellular
humor
adapt
immun
evolutionari
tug
war
host
pathogen
virus
develop
way
circumv
even
take
advantag
host
respons
also
becom
clear
much
damag
disrupt
physiolog
caus
viral
infect
due
direct
cytopath
effect
viru
side
effect
misdirect
overexuber
host
immun
multilay
natur
host
defens
virus
complex
interplay
pathogen
host
immun
system
impact
normal
tissu
function
call
holist
approach
studi
viral
pathogenesi
go
forward
rather
drill
function
specif
viral
protein
look
singular
put
mechan
host
protect
studi
done
past
sever
decad
need
think
system
level
integr
inform
across
biolog
scale
gene
protein
cell
organ
across
time
across
interact
direct
viru
host
host
viru
host
host
accomplish
excit
news
tool
permit
us
collect
quantit
data
aspect
hostpathogen
interplay
anim
model
virus
encod
fluoresc
protein
advanc
microscop
allow
deep
longterm
highresolut
imag
mani
tissu
organ
live
anim
report
system
reveal
ident
immun
cell
molecular
state
permit
investig
observ
viral
spread
concomit
host
respons
real
time
novel
method
tissu
prepar
allow
even
entir
organ
made
access
high
resolut
confoc
imag
dozen
color
enabl
detail
phenotyp
analysi
infiltr
immun
cell
locat
viru
state
host
cell
gerner
et
al
emerg
tool
dna
rna
situ
hybrid
permit
document
transcript
respons
infect
applic
tool
produc
detail
four
dimension
volum
time
pictur
viru
spread
natur
host
respons
anim
given
candid
vaccin
drug
tool
also
use
directli
visual
specif
effect
treatment
infect
host
respons
immun
organrel
power
imag
becom
combin
emerg
method
system
biolog
insight
gain
rapidli
especi
true
emerg
reemerg
infect
frequent
sever
effect
host
homeostasi
new
understand
infecti
process
host
respons
need
transcriptom
proteom
metabol
analys
becom
access
power
applic
even
human
host
nakaya
et
al
allow
collect
data
set
compar
anim
model
determin
extent
anim
system
suitabl
substrat
vaccin
drug
develop
one
stick
point
go
forward
limit
capac
mani
investig
integr
enorm
data
set
technolog
gener
becom
challeng
interpret
data
context
human
genet
variat
microbiom
differ
critic
impact
immun
perform
investig
come
field
remark
opportun
address
question
viral
pathogenesi
way
establish
scientist
abl
employ
howev
case
rise
scientist
embrac
need
train
quantit
analysi
also
scientif
enterpris
must
provid
suitabl
incent
larg
multidisciplinari
team
need
collect
mine
mani
type
inform
requir
systemslevel
understand
infecti
process
germain
et
al
reductionist
biolog
near
extinct
point
futur
analyz
biolog
integr
holist
manner
imag
help
us
understand
cell
dynam
migrat
posit
cellcel
interact
critic
immun
effector
respons
rang
cytokin
chemoattract
work
facet
immun
central
determin
occur
face
viral
infect
variou
cell
factor
contribut
maintain
host
homeostasi
disrupt
informat
analysi
comput
model
provid
new
way
integr
dispar
data
set
yin
yang
immun
function
infect
better
understood
precis
understand
tip
point
augment
blockad
could
play
key
role
potenti
improv
health
outcom
rise
virologist
need
becom
physiologist
appreci
entir
organ
behav
face
infect
insight
determin
lever
need
reduc
morbid
mortal
infect
absenc
fulli
protect
vaccin
inde
determin
compon
immun
respons
best
suit
protect
futur
excit
demandingw
need
scienc
new
way
move
forward
effici
manner
although
challeng
system
biolog
approach
potenti
vastli
acceler
capac
understand
origin
virusinduc
patholog
develop
novel
way
prevent
cellular
immun
critic
control
viral
diseas
understand
viral
pathogenesi
alway
somewhat
limit
abil
measur
cellular
immun
respons
one
first
assay
tcell
function
enzymelink
immunospot
elispot
techniqu
revolutionari
abil
quantit
antigenspecif
cytokin
product
singlecel
level
follow
intracellular
cytokin
stain
ic
flow
cytometri
similarli
appli
detect
antigenspecif
cell
year
later
sinc
growth
multicolor
flow
cytometri
capabl
led
ic
assay
provid
inform
multipl
cytokin
phenotyp
marker
combin
mhcpeptid
multim
stain
well
degranul
via
export
also
assess
togeth
ic
number
tcell
cytokin
differenti
marker
interest
grown
tremend
year
tcell
assay
develop
interest
protect
capac
virusspecif
cell
express
exhaust
marker
costimulatori
marker
like
cytokin
relev
expand
tradit
includ
other
intracellular
level
granzym
perforin
import
tcell
function
chemokin
receptor
give
clue
tcell
cytokin
profil
function
pattern
also
mani
marker
defin
regulatori
tcell
subset
impact
function
effector
cell
addit
tcell
marker
recent
evid
shown
nk
cell
memori
properti
contribut
control
infect
dendrit
cell
import
prime
sustain
tcell
respons
may
serv
vehicl
viral
spread
viru
infect
dengu
bcell
lineag
magnitud
plasmablast
correl
dengu
diseas
sever
thu
reason
quantit
andor
phenotyp
virtual
everi
type
immun
cell
subset
look
correl
immun
pathogenesi
fortun
technolog
recent
emerg
greatli
increas
number
marker
simultan
quantit
singlecel
level
compar
tradit
flow
cytometri
mass
cytometri
cytof
cytometri
time
flight
base
use
heavi
metal
ion
label
rather
fluorophor
tag
antibodi
probe
tanner
et
al
consequ
readout
mass
spectrometri
yield
two
parallel
benefit
mani
channel
simultan
detect
littl
spillov
result
paramet
flow
cytometri
without
need
perform
interchannel
compens
alreadi
mass
cytometri
appli
studi
immun
cell
signal
capac
bendal
et
al
bodenmil
et
al
phenotyp
divers
cell
newel
et
al
nk
cell
horowitz
et
al
b
cell
bendal
et
al
measur
immun
compet
cancer
patient
chang
et
al
find
immun
correl
respons
surgeri
gaudillier
et
al
variat
techniqu
even
adapt
read
cell
tissu
section
kind
extens
immunohistochemistri
paramet
angelo
et
al
masstag
antibodi
conjug
readili
avail
mani
marker
abil
build
highdimension
panel
becom
easier
although
expens
rel
lack
spillov
panel
design
simpler
though
entir
foolproof
leipold
et
al
drawback
techniqu
addit
cost
expertis
requir
set
maintain
complex
instrument
two
major
drawback
acquisit
speed
cell
recoveri
word
cytof
slow
collect
cell
major
cell
lost
secondari
drawback
sensit
sinc
channel
mass
cytomet
equal
sensit
phycoerythrin
pe
similarli
bright
fluorochrom
fluoresc
flow
cytometri
despit
drawback
wealth
inform
collect
cytof
make
techniqu
choic
broad
deep
profil
immun
cell
mani
laboratori
use
method
find
cellular
immun
biomark
infect
pathogenesi
immun
note
mass
cytometri
techniqu
provid
highli
multiparametr
data
singlecel
level
technic
possibl
wholetranscriptom
rnaseq
singl
cell
jaitin
et
al
target
version
technolog
also
use
target
rnaseq
use
pcr
amplifi
set
gene
cdna
singl
cell
amplifi
product
cell
barcod
pool
deep
sequenc
provid
altern
cytof
limit
avail
good
antibodi
target
molecul
hand
gener
transcript
frequenc
rather
protein
abund
parallel
measur
thousand
immun
cell
creat
complex
data
deciph
potenti
biomark
develop
visual
statist
algorithm
help
interpret
cytof
data
continu
grow
current
publish
cluster
algorithm
appli
mass
cytometri
includ
spade
simond
et
al
pca
newel
et
al
visn
amir
et
al
citru
bruggner
et
al
accens
shekhar
et
al
next
year
like
see
refin
select
algorithm
perform
best
particular
question
summari
may
predict
futur
studi
viral
interact
immun
system
domin
bigdata
approach
mass
cytometri
singlecel
target
rnaseq
comput
method
deciph
larg
data
set
key
find
biomark
hidden
within
anim
resid
microb
ever
sinc
anim
least
million
year
mostli
prokaryot
bacteria
archaea
wherev
bacteria
also
virus
live
whether
ocean
human
bodi
rey
et
al
minot
et
al
pride
et
al
bacteriophag
predat
bacteri
host
relationship
multifacet
complex
mark
competit
cooper
tension
forc
everpres
dynam
mani
bacteri
speci
live
within
anim
host
compet
nich
virus
within
bacteri
host
longstand
ecosystem
repres
human
bodi
virus
predict
affect
fit
immedi
bacteri
host
rey
et
al
minot
et
al
tundra
wolf
keep
carib
healthi
inevit
forc
viral
predat
affect
bacteri
popul
therefor
larger
host
resid
rey
et
al
addit
bacteriophag
domin
virus
human
commens
virus
also
live
directli
cell
new
nucleotidebas
approach
show
teem
resid
human
virus
skin
mouth
nose
vagina
seem
carri
detect
dna
virus
time
wyli
et
al
press
familiar
caus
common
usual
mild
occasion
sever
infect
cytomegaloviru
epsteinbarr
viru
two
excel
exampl
focu
ill
effect
peopl
carri
virus
silent
decad
essenti
life
parasit
exploit
us
purpos
rel
low
biolog
cost
human
fit
benefit
relationship
mostli
hidden
disciplin
microbiolog
new
organ
discov
pathogen
pathogen
becam
domin
mindset
virus
even
organ
infect
us
persist
decad
time
without
clinic
consequ
although
herpesvirida
jc
viru
certain
papillomavirus
exampl
may
caus
ill
may
lethal
net
neg
effect
integr
across
life
span
entir
human
popul
extrem
low
cost
side
human
fit
low
possibl
even
small
benefit
across
peopl
may
cumul
greater
drive
toward
microbiolog
perfect
may
produc
paradox
worsen
health
remov
benefit
well
endow
immun
divid
adapt
innat
increas
evid
third
class
may
call
microbi
commens
longtim
partner
among
function
help
protect
motherland
human
host
mani
observ
indic
commens
bacteria
part
protect
invad
organ
bohnoff
et
al
alreadi
report
commens
virus
may
help
control
seriou
infect
barton
et
al
barr
et
al
predict
evid
relationship
grow
come
year
medic
scienc
focus
horizont
consequ
often
sever
numer
vertic
may
least
import
evolutionari
interest
commens
whether
bacteri
virus
protect
us
time
tension
come
necess
transmit
next
host
exce
protect
properti
final
seemingli
unpleas
thought
must
die
scientist
consequ
age
altern
view
clocklik
marker
phenomena
age
select
speci
orderli
senesc
fare
better
herd
subject
cull
regardless
age
pathogen
sweep
popul
kill
young
old
alik
case
lead
extinct
entir
group
clockimpos
senesc
appear
safer
mathemat
model
indic
commens
contribut
age
human
may
contribut
causat
cancer
think
helicobact
pylori
ebviru
hepat
b
degen
diseas
jk
viru
prion
loglinearli
agerel
commens
may
contribut
kill
us
safe
agerel
manner
without
epidem
risk
commun
blaser
webb
bad
individu
may
good
speci
biolog
premis
correct
one
implic
commens
virus
includ
may
benefici
us
earli
life
reproduct
age
costli
later
rather
tri
prevent
infect
earli
might
welcom
least
part
control
untoward
consequ
focu
better
lateinlif
control
lessvirul
commens
may
protect
higher
virul
organ
even
speci
one
exampl
perhap
children
expos
varicellazost
viru
earli
eon
control
seriou
ill
effect
antivir
drug
age
might
boost
vzv
immun
vaccin
prevent
seriou
consequ
approach
would
need
test
conclus
clearli
viral
pathogensthey
mostli
exogenousthat
cross
anim
histor
danger
sar
ebola
mer
variant
influenza
shown
us
introduct
continu
howev
also
endow
mani
viral
commens
new
type
discov
regular
rey
et
al
rey
et
al
minot
et
al
wyli
et
al
press
biolog
relationship
complex
commens
viru
symbiot
pathogen
depend
host
context
time
biospher
full
conting
deep
understand
underli
biolog
viral
commens
allow
us
har
friendli
microb
improv
human
health
bruce
beutler
direct
center
genet
host
defens
ut
southwestern
medic
center
dalla
analyz
immun
function
mammal
random
germlin
mutagenesi
share
nobel
prize
physiolog
medicin
discoveri
concern
activ
innat
immun
understand
precis
virus
work
defeat
genet
continu
lead
way
understand
precis
molecular
interact
viru
host
number
remark
tool
becom
avail
probe
precis
virus
work
today
possibl
ask
protein
host
essenti
viru
x
complet
life
cycl
mice
whole
organ
level
genet
deliv
answer
question
kind
greater
speed
ever
soon
new
phenotyp
observ
exampl
instanc
mice
normal
virul
viru
fail
prolifer
one
confid
state
mutat
host
genom
respons
phenotyp
new
realiti
stem
develop
massiv
parallel
sequenc
platform
method
highspe
genotyp
new
comput
tool
express
purpos
moresco
beutler
bull
et
al
wang
et
al
latter
develop
laboratori
detail
descript
offer
short
essay
realtim
forward
genet
analysi
mous
work
approxim
follow
male
mice
known
sequenc
homozyg
loci
usual
background
expos
mutagen
enu
nethylnnitrosourea
induc
singl
base
pair
chang
genom
dna
spermatogonia
sever
thousand
mutat
transmit
sperm
caus
code
chang
gene
per
haploid
genom
mutat
transmit
male
breed
mutagen
sire
femal
male
produc
week
male
subject
deep
whole
exom
sequenc
detect
mutat
caus
may
caus
code
chang
sperm
preserv
male
use
produc
daughter
ten
daughter
backcross
sire
yield
progeni
progeni
releas
screen
genotyp
mutant
site
determin
whether
homozyg
wt
ref
heterozyg
het
homozyg
variant
var
foreknowledg
genotyp
assur
phenotyp
measur
immedi
comput
determin
linkag
made
use
recess
semidomin
domin
inherit
model
gener
linkag
observ
phenotyp
genet
basi
linkag
observ
often
indic
unambigu
caus
effect
ie
show
particular
mutat
respons
phenotyp
mice
process
week
mous
bear
mutat
mutat
investig
week
phenotyp
consequ
mani
phenotyp
actual
studi
parallel
annual
mutat
examin
time
everi
gene
struck
repeatedli
mutat
mani
allel
test
phenotyp
effect
take
long
gene
examin
consider
depth
may
consid
implic
exoner
phenomenon
interest
put
null
allel
concern
caus
prematur
truncat
protein
aberr
splice
three
observ
homozyg
state
consid
ampl
test
import
gene
phenomenon
interest
simpl
mendelian
trait
link
mutat
complex
trait
involv
mutat
multipl
loci
solv
well
particularli
pedigre
larg
size
construct
purpos
contrast
quantit
trait
locu
map
enu
mutagenesi
tend
produc
monogen
phenotyp
complex
phenotyp
observ
easili
solv
owe
limit
number
mutat
investig
fact
complex
trait
occur
even
mutat
caus
code
chang
given
pedigre
suggest
interact
natur
occur
mutat
abund
may
repres
major
sourc
phenotyp
observ
wild
popul
human
cours
would
presum
appli
phenotyp
includ
viral
suscept
phenotyp
enu
mutagenesi
offer
explan
work
complex
biolog
system
tell
us
precis
fight
virus
virus
take
advantag
host
give
us
good
start
futur
may
call
even
sophist
method
forward
genet
present
practic
alreadi
widespread
use
technolog
modifi
genom
quit
possibl
creat
mani
target
mutat
within
given
model
organ
genom
probe
interact
pathway
might
thought
redund
function
yet
innov
run
cours
futur
may
reli
upon
synthet
genom
alreadi
possibl
creat
design
microb
genom
modifi
investig
choos
complet
chromosom
eukaryot
organ
yeast
synthes
well
day
come
may
synthes
genom
mous
modifi
choos
like
ye
like
mice
answer
question
address
use
current
gener
genomemodifi
technolog
undoubtedli
cascad
futur
technic
advanc
continu
elucid
interact
host
pathogen
first
test
tube
synthesi
viru
cello
et
al
caus
global
uproar
one
axiom
biolog
hold
prolifer
cellular
organ
virus
depend
presenc
function
genom
cellfre
synthesi
polioviru
violat
law
natur
templat
requir
recreat
organ
peopl
prepar
accept
new
realiti
virus
exist
infecti
particl
natur
well
entri
databas
surprisingli
respons
laymen
expert
alik
includ
prais
ethic
concern
ridicul
fierc
condemn
wimmer
wimmer
paul
total
synthesi
virus
meanwhil
come
age
yet
number
synthet
virus
tabl
technolog
need
produc
larg
segment
dna
stitch
togeth
far
effici
moreov
price
errorfre
synthet
oligonucleotid
nucleotid
still
significantli
greater
predict
bp
revolut
howev
brew
notka
et
al
kosuri
church
even
though
new
technolog
yet
reach
commerci
sector
predict
new
strategi
drastic
chang
research
molecular
genet
biolog
engin
tediou
stepsconstruct
vector
sitespecif
mutant
etcwil
soon
replac
fast
afford
dna
synthesi
templatefre
synthesi
rna
virus
cours
reli
chemic
synthesi
genomecomplementari
doubl
strand
dna
refer
cdna
cdna
turn
enzymat
transcrib
viral
rna
ultim
convert
infecti
viru
chemic
synthesi
cdna
discuss
reminisc
enzymat
synthesi
cdna
retroviru
revers
transcriptas
introduc
charl
weissmann
colleagu
taniguchi
et
al
weissmann
strategi
term
revers
genet
led
revolutionari
method
allow
dnabas
genet
manipul
rna
virus
howev
wherea
weissmann
strategi
requir
natur
viral
isol
gener
cdna
figur
chemic
synthesi
need
genom
sequenc
inform
readili
avail
internet
figur
b
assum
sequenc
rna
known
believ
enzymat
synthesi
cdna
soon
replac
chemic
synthesi
wimmer
paul
owe
properti
quasi
speci
high
spontan
mutat
frequenc
cycl
rna
replic
rna
viru
genom
gener
much
smaller
around
nucleotid
dna
viru
genom
bp
moreov
among
terrestri
virus
rna
virus
outnumb
dna
virus
ratio
henc
surpris
chemic
synthesi
virus
far
target
predominantli
rna
virus
tabl
expect
revolut
dna
synthesi
excit
novel
strategi
manipul
assembl
larg
synthet
dna
molecul
gibson
et
al
like
result
chemic
synthes
mani
dna
virus
tabl
summar
exampl
synthet
virus
roughli
chronolog
order
question
linger
purpos
synthes
virus
independ
natur
isol
importantli
chemic
synthesi
viral
genom
allow
investig
structur
function
organ
biolog
extent
hitherto
imposs
howev
differ
viru
synthesi
project
differ
object
briefli
mention
wimmer
paul
discuss
project
detail
synthes
ii
tabl
serv
proof
principl
regrett
synthesi
discuss
societ
implic
work
possibl
applic
cut
scienc
editor
cello
et
al
wimmer
gener
phage
describ
synthesi
ii
improv
upon
methodolog
dramat
shorten
time
requir
accur
assembl
kb
segment
dna
synthet
oligonucleotid
entir
synthesi
phage
consum
week
ii
tabl
synthes
iii
vi
vii
ix
serv
identifi
beyond
doubt
histori
ident
andor
pathogenesi
import
human
pathogen
wimmer
paul
includ
notabl
spanish
flu
influenza
viru
organ
disappear
year
devast
pandem
iii
infecti
simian
immunodefici
viru
sivcpz
vii
infecti
bat
sarslik
coronaviru
ix
latter
studi
demonstr
use
genet
wholegenom
synthesi
investig
cello
et
al
tran
speci
movement
zoonos
reconstitut
infecti
human
endogen
retroviru
hervk
vi
remnant
human
genom
may
yield
valuabl
clue
impact
endogen
retrovirus
human
evolut
synthes
iv
v
viii
x
xiii
xv
xvi
describ
design
virus
larg
segment
genom
recod
purpos
either
studi
function
iv
modifi
express
viral
genet
element
latter
focus
express
protein
recod
open
read
frame
either
chang
codon
bia
v
codon
pair
bia
viii
x
xiii
xv
xvi
author
commentari
view
codon
pair
deoptim
promis
new
strategi
design
new
vaccin
candid
viii
tabl
synthesi
xii
entir
orf
polioviru
genom
recod
therebi
mutat
nucleotid
encod
polyprotein
led
discoveri
two
redund
rna
regulatori
element
involv
rna
replic
synthesi
xi
seed
viru
develop
vaccin
synthes
avoid
licens
problem
regulatori
author
prove
import
bypass
creat
commerci
product
target
human
diseas
final
cooper
report
synthesi
tobacco
mosaic
viru
tmv
synthesi
xiv
first
plant
viru
origin
discov
beijerinck
tmv
one
research
virus
time
yet
cooper
chose
titl
public
proof
synthesi
tobacco
mosaic
viru
curious
refer
classic
code
chemist
consid
synthesi
ultim
proof
deciph
chemic
structur
cello
colleagu
also
made
refer
code
cello
et
al
signific
proof
read
synthesi
nucleotid
sequenc
deposit
sequenc
databas
see
also
ref
conclud
remind
reader
synthet
biolog
repres
dual
use
dilemma
technolog
use
legitim
benefit
humankind
misus
terror
quandari
refer
dual
use
research
wimmer
paul
nation
research
council
noth
better
match
definit
templatefre
synthesi
virus
one
hand
advanc
understand
organ
lead
new
method
protect
us
viral
diseas
yet
hand
could
exploit
malici
intent
optim
enthusiasm
predict
futur
applic
synthet
virolog
vastli
construct
destruct
genomewid
associ
studi
gwa
highthroughput
dna
sequenc
often
refer
next
gener
sequenc
ng
offer
excit
new
opportun
diagnosi
treatment
viral
diseas
evolv
technolog
lead
new
era
precis
also
known
person
medicin
approach
base
fact
common
variant
host
genom
may
profound
influenc
cours
viral
infect
respons
treatment
two
exampl
illustr
potenti
precis
medicin
host
viral
genom
variat
determin
respons
current
standard
care
hepat
c
use
ng
diagnost
test
identifi
microbi
pathogen
recent
mainstay
standard
care
hepat
c
antivir
drug
requir
week
therapi
pegyl
interferon
pegintron
ribavirin
associ
signific
side
effect
patient
achiev
sustain
viral
respons
svr
pegintronribavirin
mani
furthermor
patient
africanamerican
hispan
descent
respond
well
possibl
identifi
individu
among
popul
like
respond
gwa
compar
respond
nonrespond
popul
identifi
singl
nucleotid
polymorph
near
interferon
respons
gene
segreg
svr
explain
signific
proport
variat
respons
ge
et
al
natur
patient
homozyg
cc
nucleotid
show
success
outcom
homozyg
tt
nucleotid
success
outcom
tt
genotyp
frequent
africanamerican
explain
lower
respons
rate
data
new
therapi
hepat
c
rapidli
evolv
toward
potenti
cure
howev
even
newer
rna
polymeras
proteas
inhibitor
variat
respons
base
host
viral
genotyp
thu
use
gwa
like
valu
respond
stratif
treatment
hepat
c
also
viru
diseas
six
hepat
c
sequencespecif
genotyp
variant
differ
respons
newli
avail
antivir
therapi
includ
viral
rna
polymeras
inhibitor
sofosbuvir
proteas
inhibitor
simeprevir
impair
viral
entri
mammalian
cell
shown
tabl
hepat
c
genotyp
determin
best
therapeut
strategi
hepat
c
thu
provid
valuabl
case
studi
host
pathogen
genet
variat
influenc
treatment
choic
outcom
infecti
diseas
flagship
person
diagnost
medicin
divers
strategi
identif
microbi
pathogen
sensit
antibiot
mani
case
diagnost
test
take
daysfor
exampl
least
h
growth
blood
cultur
follow
addit
day
requir
cultur
organ
determin
sensit
gwa
bodili
tissu
fluid
obtain
dna
librari
prepar
repres
dna
sampleboth
host
microbi
pathogen
unbias
massiv
parallel
sequenc
perform
human
dna
sequenc
remov
consider
microbi
sequenc
align
comprehens
databas
contain
dna
sequenc
known
human
microbi
pathogen
enabl
rapid
identif
organ
often
predict
sensit
antibiot
follow
exampl
focus
use
ng
identifi
bacteri
pathogen
immun
compromis
host
howev
viral
sequenc
nonpathogen
strain
also
identifi
demonstr
approach
equal
applic
rapid
diagnosi
viral
pathogen
boy
sever
combin
immunodefici
diseas
develop
fever
progress
worsen
headach
comprehens
diagnost
workup
includ
blood
cultur
serolog
cerebrospin
fluid
csf
neg
laboratori
data
consist
either
viral
mening
potenti
autoimmun
enceph
discharg
without
antibiot
therapi
patient
subsequ
progress
readmit
progress
sever
neurolog
diseas
point
inform
consent
cerebrospin
fluid
obtain
unbias
massiv
parallel
dna
sequenc
total
sequenc
among
total
read
correspond
spirochet
leptospira
known
sensit
penicillin
ng
also
identifi
sever
microb
includ
nonpathogen
viral
speci
anellovirida
demonstr
abil
detect
viral
sequenc
total
day
highdos
penicillin
patient
show
evid
clinic
improv
ultim
discharg
home
nearli
full
recoveri
premorbid
state
singl
case
report
suggest
possibl
futur
singl
testunbias
massiv
parallel
sequenc
relev
tissu
bodili
fluidcould
use
rapid
identif
microbi
pathogen
sensit
seem
unlik
approach
would
supplant
convent
approach
microbi
pathogen
detect
howev
may
use
adjunct
case
one
provoc
conceiv
ng
could
ultim
singl
test
perform
microbi
identif
sensit
test
virus
select
replic
lyse
cancer
cell
leav
normal
cell
intact
known
oncolyt
fact
oncolyt
virus
ov
multimod
therapeut
capabl
lyse
cancer
cell
also
modul
tumor
microenviron
collaps
tumor
vasculatur
abil
engag
multipl
therapeut
pathway
clear
potenti
benefit
sinc
cancer
treatment
design
appli
therapeut
pressur
singl
tumor
target
trigger
antigen
shift
ultim
develop
tumor
resist
rel
recent
begun
understand
immun
respons
trigger
ov
also
critic
role
antitumor
efficaci
consequ
strategi
design
enhanc
ov
immun
engag
repres
key
research
focu
wildtyp
ov
ideal
agent
shift
tumor
immun
microenviron
tolerogen
antigen
lyse
tumor
cell
creat
inflammatori
condit
load
damageand
pathogenassoci
molecular
signal
whose
level
increas
replic
proce
inde
replic
requir
efficaci
sinc
nonrepl
virus
viruslik
particl
typic
fail
achiev
tumor
control
ultim
replic
ov
repres
selflimit
infect
sinc
suscept
tumor
cell
finit
popul
whose
avail
declin
oncolysi
begin
system
deliv
ov
target
primari
dissemin
metastat
diseas
breitbach
et
al
russel
et
al
penetr
peripher
lymphoid
compart
unlock
potenti
activ
differ
subtyp
memori
tcell
respons
durat
therapi
system
ov
infus
limit
preexist
antivir
immun
de
novo
develop
function
neutral
antibodi
ov
surprisingli
delay
allow
viru
surviv
bloodstream
month
repeat
intraven
administr
expand
clinic
develop
selfprotect
virus
clear
therapeut
valu
immun
respons
gener
ov
ultim
lead
viru
control
import
safeti
featur
also
virusinfect
tumor
cell
inde
ovactiv
antitumor
immun
mediat
object
clinic
respons
phase
iii
trial
amgen
tvec
modifi
oncolyt
herp
simplex
viru
encod
gmcsf
tumor
regress
observ
directli
inject
tumor
distant
noninject
tumor
harbor
detect
viru
kaufman
et
al
immun
activ
culmin
establish
memori
popul
protect
tumor
rechalleng
find
new
way
enhanc
tcell
memori
format
critic
establish
longterm
durabl
respons
patient
one
excit
approach
magnifi
differenti
immun
respons
favor
tumor
viral
target
encod
tumorassoci
antigen
taa
ov
genom
creat
bona
fide
ov
vaccin
bridl
et
al
oncolyt
vaccin
design
expand
natur
establish
memori
cell
recogn
tumorspecif
target
exampl
human
cytomegaloviru
hcmv
antigen
detect
sever
tumour
type
includ
glioma
neuroblastoma
approxim
cancer
patient
hcmvspecif
memori
cell
establish
past
infect
activ
oncolyt
vaccin
encod
hcmv
taa
altern
tumorreact
cell
artifici
prime
anoth
vaccin
vector
express
share
taa
follow
ov
infus
primeboost
regimen
bridl
et
al
boost
immun
system
engag
continu
central
theme
field
oncolyt
virotherapi
ov
natur
condit
tumor
microenviron
attract
cell
maintain
local
activ
nishio
et
al
pair
ov
immunomodulatori
therapi
promot
antitumor
immun
respons
excit
approach
partner
therapi
may
rang
tradit
chemoand
radiotherapi
cut
edg
techniqu
antibodymedi
immun
checkpoint
inhibit
adopt
cell
therapi
act
pair
ov
alreadi
shown
improv
control
metastat
melanoma
beyond
observ
either
treatment
alon
zamarin
et
al
similarli
act
shown
clinic
benefit
standalon
treatment
multipl
malign
show
preclin
promis
combin
ov
rommelfang
et
al
either
therapi
alon
may
fail
coadministr
compens
solo
defici
render
heterogen
tumor
suscept
therapi
oncolyt
virotherapi
repres
excit
approach
treatment
malign
diseas
effort
need
consolid
abil
ov
activ
immun
cell
appropri
antigen
tumor
target
improv
recruit
infiltr
immun
cell
tumor
microenviron
maintain
situ
activ
new
therapeut
target
strategi
continu
uncov
hostviru
screen
program
mahoney
et
al
inform
mathemat
model
bailey
et
al
le
boeuf
et
al
greater
effort
map
complex
interact
ov
host
cell
context
expand
immun
respons
uncov
new
therapeut
opportun
initi
undoubtedli
gener
anticanc
respons
substanti
enhanc
tumor
regress
also
extend
tumorfre
surviv
protect
regrowth
relaps
prion
protein
adopt
altern
conform
becom
selfpropag
prusin
gener
one
conform
rich
conform
prone
polymer
amyloid
fibril
look
futur
prion
biolog
diseas
rich
univers
previous
unknown
biolog
begin
emerg
prusin
number
differ
physiolog
prion
particularli
mammal
steadili
increas
physiolog
prion
play
role
variou
normal
function
rang
longterm
memori
innat
immun
metabol
adapt
fungal
incompat
xu
et
al
similarli
list
neurodegen
diseas
caus
prion
expand
jucker
walker
prusin
last
year
evid
continu
accumul
argu
alzheim
parkinson
diseas
well
multipl
system
atrophi
tauopathi
huntington
diseas
caus
prion
watt
et
al
watt
et
al
seem
like
addit
huntington
diseas
polyq
polyglutamin
disord
includ
spinocerebellar
ataxia
prion
diseas
sever
import
new
concept
emerg
studi
prion
first
prion
creat
novel
mechan
wherebi
physiolog
function
regul
almost
instantan
shift
conform
protein
one
structur
state
anoth
prusin
second
prion
often
featur
diseas
particular
protein
accumul
insid
cell
found
neurofibrillari
tangl
lewi
bodi
glial
cytoplasm
inclus
nuclear
inclus
disord
prion
accumul
outsid
cell
like
plaqu
alzheim
creutzfeldtjakob
diseas
third
strain
prion
differ
phenotyp
repres
distinct
conform
altern
fold
protein
fourth
late
onset
herit
neurodegen
diseas
seem
like
explain
convers
mutant
caus
protein
prion
precipit
event
fifth
prion
diseas
age
depend
like
due
protein
qualiti
control
machineri
slowli
becom
less
effici
organ
age
mani
explan
late
onset
herit
neurodegen
diseas
offer
explain
manifest
fifth
sixth
even
seventh
decad
life
seem
like
initi
event
format
suffici
number
prion
stimul
sustain
selfpropag
prusin
although
mutat
patient
famili
neurodegen
diseas
demonstr
caus
disord
genet
linkag
studi
explain
late
onset
ill
remain
problemat
one
explan
stochast
event
result
suffici
number
prion
accumul
initi
sustain
infect
age
increas
frequenc
random
event
produc
prion
tandem
declin
protein
qualiti
control
machineri
conspir
produc
sustain
prion
infect
mechan
applic
inherit
sporad
prion
diseas
new
concept
may
offer
novel
approach
develop
earli
diagnost
effect
therapeut
current
drug
halt
even
slow
neurodegen
diseas
prusin
develop
pet
positron
emiss
tomographi
report
use
establish
diagnosi
earli
cours
diseas
critic
accur
earli
diagnos
like
critic
choos
appropri
therapeut
although
attempt
develop
effect
therapeut
alzheim
parkinson
diseas
costli
unsuccess
discoveri
diseas
caus
prion
offer
new
strategi
drug
discoveri
notabl
point
mutat
found
prp
protein
caus
creutzfeldtjakob
diseas
shown
domin
neg
prusin
deciph
structur
chang
mutat
initi
may
give
import
insight
could
inform
novel
therapeut
approach
drug
develop
extend
live
wildtyp
transgen
mice
inocul
mousepassag
scrapi
prion
chronic
wast
diseas
prion
respect
berri
et
al
give
promis
futur
therapeut
mani
system
diseas
found
caus
prion
unknown
certainli
much
interest
possibl
adultonset
type
ii
diabet
may
caus
prion
patient
cell
often
fill
amyloid
fibril
compos
protein
amylin
area
prion
biolog
diseas
certainli
ripe
increas
investig
knowledg
physiolog
prion
infanc
learn
prion
propag
like
offer
novel
approach
therapeut
diseas
like
alzheim
parkinson
alreadi
preval
predict
increas
human
life
expect
continu
rise
global
hivaid
pandem
continu
exact
enorm
toll
claim
million
live
alon
million
sinc
aid
recogn
three
decad
ago
worldwid
million
individu
live
hivaid
despit
daunt
statist
global
deploy
proven
treatment
prevent
strategi
slow
onslaught
hivaid
incid
infect
death
fall
onethird
past
decad
success
come
easili
result
decad
innov
begin
fundament
basic
research
led
success
intervent
inde
basic
research
hivaid
inexor
link
develop
effect
intervent
diseas
regard
develop
new
tool
treatment
prevent
hiv
facilit
detail
understand
hiv
pathogenesi
studi
viral
pathogenesi
underpin
hiv
research
perhap
tangibl
field
therapeut
detail
knowledg
replic
cycl
hiv
provid
first
target
antiretrovir
drug
arv
first
fdaapprov
arv
nucleosid
analog
zidovudin
target
revers
transcriptas
enzym
critic
compon
hiv
replic
cycl
convert
viral
rna
provir
dna
thu
allow
integr
host
cell
genom
zidovudin
first
synthes
antineoplast
agent
year
prior
discoveri
hiv
found
activ
hiv
screen
process
knowledg
hiv
replic
cycl
improv
new
class
therapeut
agent
develop
notabl
inhibitor
hiv
proteas
integras
enzym
synthes
optim
base
detail
crystal
structur
target
protein
similar
investig
yield
licens
arv
arv
combin
depend
intim
knowledg
viral
replic
cycl
arv
similarli
revolution
hiv
prevent
notabl
prevent
mothertochild
transmiss
pmtct
program
avert
million
infect
sinc
un
joint
programm
hiv
aid
unaid
arv
also
prove
effect
use
preexposur
prophylaxi
prep
uninfect
individu
treatment
prevent
tasp
taken
hivinfect
peopl
oral
prep
demonstr
efficaci
prevent
viral
acquisit
taken
prescrib
haber
et
al
landmark
studi
hptn
demonstr
valu
tasp
wherebi
antiretrovir
therapi
art
given
infect
partner
serodiscord
coupl
lower
viral
load
thu
reduc
risk
transmit
viru
uninfect
sexual
partner
cohen
et
al
arvbas
prevent
modal
combin
intervent
condom
voluntari
medic
male
circumcis
provid
build
block
comprehens
prevent
program
understand
pathogen
mechan
hiv
infect
detail
immun
respons
viru
also
critic
develop
safe
effect
vaccin
prevent
hiv
infect
regard
develop
effect
hiv
vaccin
formid
challeng
due
fact
natur
immun
respons
hiv
inadequ
control
certainli
elimin
viru
decad
disappoint
clinic
trial
first
vaccin
aim
induct
humor
immun
cellbas
tcell
vaccin
fail
produc
effect
immun
respons
trial
thailand
offer
first
sign
clinic
efficaci
reduct
viral
acquisit
rerksngarm
et
al
regimen
canarypox
vector
prime
recombin
boost
appear
elicit
nonor
weakli
neutral
antibodi
region
envelop
trimer
repres
first
moder
success
studi
hiv
vaccin
candid
human
reinvigor
field
hiv
vaccinolog
simultan
research
deepen
understand
immun
respons
hiv
discov
broadli
neutral
antibodi
bnab
induc
cours
chronic
infect
curiou
bnab
produc
minor
infect
individu
usual
year
infect
liao
et
al
serial
blood
sampl
taken
acut
infect
donor
reveal
coevolut
viral
mutat
broaden
humor
immun
respons
viru
end
year
hypermut
broadli
reactiv
antihiv
antibodi
evolv
togeth
highli
mutat
viru
continu
tri
escap
immun
respons
therefor
tri
evad
evolv
antibodi
viru
ultim
stimul
bnab
product
paradox
hiv
immunolog
current
research
aim
determin
bnab
prevent
treat
hiv
infect
success
major
challeng
hiv
vaccinolog
induc
antibodi
via
appropri
immunogen
recent
potenti
bnab
whether
infus
directli
produc
vivo
gene
insert
administ
via
viral
vector
prevent
treat
infect
demonstr
anim
model
balaz
et
al
shingai
et
al
barouch
et
al
regard
vaccinologist
attempt
recapitul
rapid
expediti
manner
natur
immun
respons
seen
minor
infect
individu
primeboost
vaccin
regimen
specif
identifi
viral
envelop
epitop
induc
bnab
natur
infect
express
immunogen
induc
bcell
matur
toward
bnabproduc
cell
thu
understand
complex
hiv
pathogenesi
offer
new
hope
moder
effect
hiv
vaccin
research
toward
cure
hiv
infect
also
close
link
understand
hiv
pathogenesi
pursu
cure
import
first
defin
goal
work
simpli
put
cure
indefinit
remiss
diseas
follow
cessat
art
hiv
could
come
one
two
formsvir
erad
sustain
virolog
remiss
svr
latter
viru
would
remain
low
level
absenc
daili
art
famou
case
berlin
patient
offer
evid
erad
possibl
still
relianc
hematopoiet
stemcel
transplant
unlik
feasibl
certainli
riski
major
infect
individu
novel
scientif
approach
employ
geneedit
techniqu
engin
ex
vivo
mutat
coreceptor
hiv
autolog
cell
follow
reinfus
donor
host
thu
render
resist
hiv
infect
teba
et
al
effort
earli
stage
discoveri
howev
merit
attent
case
mississippi
child
offer
evid
svr
possibl
infant
infect
hiv
utero
start
art
within
h
birth
art
continu
month
point
child
lost
follow
stop
treatment
child
repres
care
month
later
trace
replic
compet
viru
statu
persist
month
viru
ultim
rebound
persaud
et
al
nation
institut
allergi
infecti
diseas
niaid
case
indic
treatment
soon
infect
minim
elimin
hiv
reservoir
result
longterm
svr
translat
experi
adult
could
possibl
evidenc
patient
franc
treat
acut
hiv
infect
maintain
svr
treatment
interrupt
et
al
howev
result
need
confirm
addit
studi
establish
svr
absenc
continu
art
broader
popul
like
requir
adjuv
therapi
therapeut
vaccin
passiv
infus
bnab
follow
initi
suppress
viremia
summari
develop
effect
intervent
prevent
treatment
hiv
infect
critic
hope
control
ultim
end
hiv
aid
pandem
heavili
depend
indepth
understand
viral
immun
pathogenesi
hiv
diseas
progress
understand
pathogenesi
viral
infect
stimul
innov
approach
develop
vaccin
work
build
upon
insight
basic
scienc
includ
virolog
microbiolog
immunolog
molecular
biolog
genet
addit
advanc
biotechnolog
gener
altern
platform
elicit
specif
immun
respons
facilit
develop
nextgener
vaccin
final
tool
molecular
medicin
provid
new
insight
immun
respons
induc
vaccin
well
associ
advers
reaction
understand
acceler
clinic
vaccin
develop
identif
biomark
predict
success
protect
respons
togeth
underli
scienc
lay
groundwork
develop
promis
vaccin
safe
efficaci
protect
varieti
pathogen
basic
scienc
understand
tand
bcell
differenti
well
detail
antigen
recognit
signal
lead
insight
pathway
immun
matur
recent
research
also
help
identifi
structur
featur
antigen
requir
elicit
specif
immun
respons
exampl
possibl
identifi
determin
antigen
engag
germlin
b
cell
promot
differenti
memori
b
cell
produc
broadli
neutral
antibodi
influenza
lingwood
et
al
similarli
understand
tcell
biolog
matur
signal
transduct
follow
interact
antigenpres
dendrit
cell
point
ration
approach
immunogen
design
led
improv
adjuv
way
modul
balanc
immun
progress
understand
innat
immun
includ
tlr
signal
interferon
activ
rigi
stimul
provid
tool
select
activ
suppress
pathway
need
futur
abil
develop
smallmolecul
agonist
antagonist
immunesuppress
target
checkpoint
tgfbeta
inhibitor
empow
effort
abil
util
biolog
therapi
monoclon
antibodi
nanoparticl
peptid
provid
divers
effect
way
elicit
durabl
tcell
respons
mediat
protect
cellular
immun
approach
increas
likelihood
success
mani
challeng
infecti
diseas
agent
cytomegaloviru
ebola
marburg
virus
similarli
har
elicit
protect
antibodi
respons
tool
could
enabl
develop
univers
influenza
vaccin
better
protect
public
health
strain
drift
emerg
new
influenza
viru
pathogen
anim
reservoir
advanc
dna
sequenc
alreadi
enabl
rapid
ration
respons
evolv
outbreak
identif
mutat
render
vaccin
ineffect
genet
analysi
routin
perform
influenza
ebola
virus
understood
structur
implic
mutat
ration
design
new
vaccin
counter
viral
resist
enhanc
addit
molecular
epidemiolog
understood
becom
increasingli
possibl
develop
preemptiv
vaccin
strategi
propos
past
avian
influenza
yang
et
al
base
understand
viral
evolut
human
immun
predict
pattern
viral
mutat
addit
genet
sequenc
pathogen
much
learn
genet
polymorph
human
human
genom
sequenc
becom
afford
routin
undoubtedli
provid
insight
optim
immunogen
also
help
probe
caus
advers
respons
may
limit
use
vaccin
immunotherapi
viral
pathogenesi
particularli
studi
viral
assembl
contribut
better
understand
synthet
biolog
facilit
new
approach
product
safe
effect
vaccin
increas
success
viruslik
particl
vaccin
encourag
immunogen
close
resembl
nativ
viru
elicit
effect
immun
particl
unabl
replic
caus
advers
respons
nextgener
improv
involv
use
synthet
biolog
nanotechnolog
kanekiyo
et
al
expect
creat
scaffold
antigen
present
surfac
better
expos
specif
epitop
viral
protein
make
possibl
target
respons
subdomin
epitop
normal
recogn
immun
respons
advanc
may
permit
target
highli
conserv
vulner
structuresnorm
protect
virusthat
induc
broad
protect
respons
immun
respons
review
ref
nabel
fauci
nabel
final
methodolog
express
engin
molecul
improv
increasingli
possibl
modul
immun
function
express
novel
molecul
genet
deliveri
antibodi
johnson
et
al
balaz
et
al
bispecif
antibodi
allow
dual
target
differ
epitop
surfac
pathogen
byrn
et
al
also
provid
mechan
redirect
immun
cell
normal
respond
specif
antigen
tool
gene
deliveri
use
produc
select
antibodi
subject
induc
make
exampl
enhanc
induct
neutral
influenza
antibodi
elderli
limberi
et
al
balaz
et
al
modul
specif
cell
recogn
antigen
determin
use
chimer
antigen
receptor
cancer
vaccin
jensen
riddel
tcell
chimer
antigen
receptor
approach
current
direct
cancer
immunotherapi
may
also
prove
efficaci
infecti
diseas
target
abil
interrog
human
immun
respons
expand
greatli
recent
year
power
technologiessuch
flow
cytometri
nanofluidicsnow
enabl
detail
qualit
quantit
interrog
human
immun
respons
similarli
abil
perform
deep
sequenc
select
tissu
immun
cell
provid
insight
ontogeni
adapt
immun
respons
time
modern
imag
techniqu
appli
vivo
facilit
understand
traffick
cell
respons
specif
stimuli
inform
lead
better
understand
mechan
immun
protect
well
definit
correl
immun
specif
pathogen
also
facilit
develop
new
vaccin
improv
exist
vaccin
confer
broader
reactiv
fewer
advers
effect
larg
number
peopl
benefit
final
import
recogn
global
surveil
viral
infect
well
rapid
intern
vaccin
distribut
greatli
assist
advanc
pathogen
detect
molecular
definit
microbi
resist
infecti
diseas
surveil
abil
electron
webbas
monitor
facilit
effort
distribut
vaccin
popul
risk
particularli
unexpect
outbreak
occur
recent
epidem
spread
ebola
viru
western
africa
highlight
rapid
emerg
pathogen
spread
across
intern
border
vaccin
repres
essenti
tool
counter
pandem
spread
infecti
diseas
preserv
public
health
welfar
peopl
throughout
world
becom
increasingli
depend
abil
provid
effect
countermeasur
emerg
infecti
diseas
threat
futur
effect
effici
develop
vaccin
well
time
distribut
increasingli
protect
public
pathogen
late
attend
retir
symposium
emin
virologist
speaker
vintag
bemoan
end
golden
age
virolog
recent
symposium
honor
life
late
hilari
koprowski
nonvirologist
speaker
ask
whether
virus
aliv
read
epilogu
book
would
firm
evid
disput
wane
statu
virolog
respond
second
would
like
add
although
virus
live
thing
critic
life
viral
sequenc
compris
genom
far
inert
endogen
retrovir
element
syncytin
exampl
essenti
placent
develop
embryo
surviv
mi
et
al
field
medic
virolog
aliv
vibrant
new
virus
continu
emerg
pose
threat
public
health
food
secur
commerc
viral
databas
rapidli
expand
investig
survey
anim
environ
use
ever
effici
inexpens
sequenc
platform
introduct
new
antivir
drug
therapeut
antibodi
vaccin
viral
diagnosi
becom
arcan
academ
exercis
evid
mount
viral
infect
contribut
chronic
diseas
includ
neurodevelopment
disord
form
cancer
virus
har
oncolog
miest
cattaneo
gene
replac
therapi
global
scale
grow
appreci
virus
contribut
element
cycl
ocean
carbon
sequestr
effect
phytoplankton
suttl
given
allot
space
focu
book
pathogenesi
touch
predict
medic
applic
encourag
reader
think
broadli
implic
virus
virolog
global
travel
trade
loss
wildlif
habitat
growth
megac
mass
migrat
due
econom
privat
polit
instabl
chang
distribut
mosquito
due
climat
chang
continu
enabl
emerg
virus
might
otherwis
remain
sequest
lipkin
recent
estim
mammal
alon
harbor
new
virus
anthoni
et
al
present
way
ascertain
viral
sequenc
data
alon
pose
substant
threat
human
wildlif
domest
anim
howev
invest
sequenc
bioinformat
system
biolog
may
translat
algorithm
allow
us
assess
potenti
host
switch
pathogen
minimum
knowledg
virus
circul
enabl
target
surveil
popul
risk
exposur
surveil
also
becom
increasingli
effici
diagnost
capac
improv
develop
world
critic
address
potenti
concern
regard
sovereignti
intellectu
properti
ensur
investig
amen
share
data
isol
public
enthusiasm
social
media
may
lead
global
viral
equival
american
gut
project
wherein
citizen
scientist
share
fecal
sampl
data
develop
human
bacteriom
databas
link
inform
concern
diet
geographi
season
health
diseas
http
humanfoodprojectcomamericangut
key
question
remain
address
whether
commens
symbiot
viral
flora
virus
like
bacteria
role
prime
regul
immun
system
virus
primarili
bacteriophag
regul
composit
abund
bacteri
flora
optimum
viral
microflora
establish
modifi
improv
diagnost
insight
role
virus
health
diseas
provid
incent
develop
antivir
drug
vaccin
armamentarium
herpesvirus
hiv
hcv
expand
includ
drug
address
chronic
infect
like
hpv
hbv
life
threaten
sequela
also
acut
selflimit
infect
eg
rhinovirus
interfer
activ
daili
live
product
present
antivir
discoveri
typic
begin
screen
massiv
compound
librari
compound
activ
modifi
optim
medicin
chemistri
brute
forc
approach
ultim
give
way
eleg
strategi
ration
drug
design
base
genom
proteom
structur
biolog
cellular
biolog
drug
target
virus
also
host
respons
contribut
viral
replic
morbid
mortal
insight
viral
biolog
evolut
host
respons
profoundli
impact
vaccin
research
vaccin
optim
expedit
develop
protect
immun
respons
enhanc
immun
young
old
increas
durat
protect
vaccin
target
conserv
conform
domain
enabl
immun
repres
higher
order
viral
taxa
rather
specif
strain
new
platform
establish
facilit
inexpens
rapid
product
atraumat
immun
final
one
wonder
peter
medawar
report
describ
virus
bad
news
wrap
protein
would
make
deliber
use
virus
medicin
virus
ideal
vector
intracellular
deliveri
genet
inform
extracellular
intracellular
determin
tropism
defin
anticip
virus
becom
increasingli
import
tool
target
destruct
neoplast
cell
express
rna
protein
enhanc
cell
function
summari
virolog
aliv
well
sang
futur
bright
got
ta
wear
shade
back
invit
write
everyon
need
know
seri
publish
oxford
univers
press
doherti
subject
rang
china
twentyfirst
centuri
cathol
church
food
polit
charg
pandem
thought
laboratori
scientist
rather
public
health
medico
epidemiologist
wonder
whether
right
person
job
perhap
triumph
optim
ration
decid
work
year
virus
immun
might
someth
use
say
also
sinc
back
swede
made
famou
deserv
cover
much
broader
remit
public
lectur
talk
legisl
forth
case
known
academ
field
also
occur
inform
individu
like
take
differ
angl
moreov
know
someth
influenza
virus
like
caus
futur
pandem
anoth
motiv
gave
chanc
talk
great
scienc
infecti
diseas
becom
past
decad
less
enthusiast
fear
monger
shock
horror
afraid
scenario
drive
mani
book
movi
emerg
pathogen
hand
also
want
make
case
day
costcut
govern
essenti
keep
public
health
servic
strong
continu
fund
research
danger
pathogen
good
level
perhap
evolutionari
histori
seem
enthusiast
militari
spend
keep
bad
guy
place
prepar
attack
bad
bug
also
import
media
hype
gainoffunct
experi
impos
excess
regul
discourag
talent
peopl
work
exot
virus
write
lay
book
subject
challeng
help
medic
infecti
diseas
colleagu
happi
talk
review
whatev
wrote
particular
seri
done
question
answer
format
odd
sit
front
comput
alon
invent
question
provid
answer
probabl
paranoid
conspiraci
theorist
oper
subject
editor
train
literatur
rather
scienc
led
exampl
challeng
chapter
summar
infect
immun
gener
reader
one
surpris
find
univers
definit
constitut
pandem
versu
epidem
pandem
alert
sound
novel
influenza
viru
spread
two
region
look
map
realiz
pretti
arbitrari
definit
escap
mutant
current
circul
flu
viru
goe
global
describ
season
epidem
though
situat
norovirus
call
pandem
diseas
got
half
wrong
ebola
go
past
histori
view
ebola
outbreak
would
jump
fast
quickli
contain
know
necessarili
lesson
expect
alreadi
overstretch
missionari
volunt
organ
like
doctor
without
border
handl
someth
like
dilatori
western
respons
direct
consequ
financi
cutback
know
get
enough
well
qualifi
boot
ground
soon
enough
also
realiz
world
need
new
econom
model
bring
antivir
drug
vaccin
post
developmenthuman
trial
phase
potenti
pandem
risk
pathogen
go
immedi
largescal
product
face
danger
outbreak
doubt
could
readi
go
ebola
money
global
respons
expect
big
pharma
without
financi
compens
take
challeng
pandem
everyon
need
know
publish
octob
even
public
around
ebola
outbreak
sale
grumbl
slowli
china
twentyfirst
centuri
lot
better
hard
get
peopl
engag
scienc
anyon
frequent
bookstor
know
whole
scienc
section
usual
smaller
altern
medicin
think
pandem
readabl
honest
inform
never
hit
sale
height
terrifi
genr
one
health
conceptu
framework
seek
establish
collabor
effort
multipl
includ
physician
veterinarian
environment
climat
scientist
other
local
nation
global
attain
optim
health
peopl
anim
environ
new
concept
one
health
gain
consider
traction
past
year
embrac
academ
institut
profession
societi
govern
avma
underli
momentum
fact
zoonos
diseas
transmiss
anim
human
repres
infecti
pathogen
human
be
emerg
infecti
diseas
write
horrif
epidem
ebola
viru
diseas
viru
carri
fruit
bat
capabl
interhuman
contact
spread
rivet
world
attent
among
emerg
infect
viral
pathogen
overrepres
sinc
agent
associ
host
speci
high
popul
turnov
densiti
surg
evolv
genet
chang
rapidli
permit
adapt
new
host
vector
speci
jump
may
infecti
low
dose
due
high
replic
capac
often
shed
secret
import
zoonot
viral
infect
human
anim
health
complex
viru
life
cycl
multifactori
caus
diseas
emerg
underli
need
integr
varieti
scientif
disciplin
studi
addit
virus
known
infect
anim
human
mani
virus
caus
diseas
anim
circul
silent
anim
includ
relat
genet
human
pathogen
hepat
crelat
flaviviru
dog
understand
agent
natur
histori
prepar
us
new
diseas
emerg
requir
collabor
effort
across
scientif
disciplin
viral
pathogenesi
key
field
investig
one
health
approach
zoonot
emerg
diseas
field
encompass
evolut
virus
includ
genet
chang
immun
pressur
mutat
recombin
reassort
may
chang
transmiss
receptor
usag
host
rang
vector
compet
virul
exampl
numer
cite
brief
account
influenza
virus
sar
coronaviru
new
world
arenavirus
chikungunya
viru
provid
exampl
minor
chang
viral
gene
encod
ligand
cell
receptor
may
result
shift
cell
tropism
host
rang
anim
reservoir
human
shift
vector
compet
caus
increas
viru
transmiss
human
elucid
factor
underli
chang
requir
collabor
effort
molecular
virologist
cell
biologist
well
expert
respons
infect
individu
organ
speci
vertebr
insect
tick
conclus
concern
multidisciplinari
approach
appli
understand
diseas
express
system
biolog
signal
transduct
pathway
caus
proinflammatori
chang
follow
viral
infect
well
innat
adapt
immun
respons
viral
protein
topic
cover
extens
book
anim
model
wide
use
studi
viral
pathogenesi
realm
compar
medicin
distinct
disciplin
experiment
medicin
design
translat
inform
anim
model
human
diseas
arguabl
clearest
exampl
one
health
principl
also
numer
exampl
import
diseas
affect
anim
provid
model
system
understand
diseas
emerg
pathogenesi
exampl
bluetongu
relat
orbivirus
epizoot
hemorrhag
diseas
deer
african
hors
sick
provid
interest
model
system
studi
viru
movement
chronic
infect
hemorrhag
fever
pathogenesi
viru
evolut
antigen
variat
porcin
respiratori
reproduct
syndrom
import
pathogen
swine
model
studi
molecular
basi
viral
virul
explain
emerg
epizoot
import
anim
diseas
mention
book
especi
relat
analog
diseas
human
eg
prion
diseas
omiss
mani
import
exampl
perhap
reflect
need
broader
one
health
approach
studi
pathogenesi
similarli
arthropod
vector
viral
infect
remain
rel
understudi
area
viral
pathogenesi
vector
critic
understand
viru
transmiss
persist
natur
evolut
illustr
need
integr
disciplin
entomolog
insect
taxonomi
physiolog
patholog
ecolog
prevent
control
vaccin
antivir
therapi
vector
control
strategi
also
reli
effect
one
health
interact
recent
review
emphas
vaccin
develop
util
benefit
interact
monath
hope
futur
one
health
vision
increasingli
inform
basic
appli
research
viral
pathogenesi
provid
fink
committe
report
us
nation
academi
scienc
delimit
dual
use
research
fairli
specif
set
experi
concern
includ
experi
involv
microb
committe
research
standard
practic
other
approach
problem
biosecur
focus
tradeoff
potenti
benefit
potenti
risk
includ
way
mitig
risk
garfinkel
et
al
aaa
baltimor
et
al
dupr
et
al
idea
benefit
share
accept
though
remain
difficult
implement
idea
risk
equal
share
difficult
analyz
work
done
problem
ethicist
polici
option
share
risk
remain
scarc
state
broadli
clearli
risk
noth
risk
someth
exampl
almost
question
must
area
influenza
viru
research
tradeoff
research
smallpox
polioviru
ebola
go
natur
occur
microb
gainoffunct
experi
provid
current
exampl
issu
recent
experi
influenza
viru
sought
identifi
genet
determin
influenza
viru
requir
produc
global
pandem
work
led
explos
controversi
whether
permit
first
place
second
place
whether
publish
fouchier
et
al
lipsitch
galvani
level
experi
subject
oversight
approv
local
institut
biosafeti
committe
suffici
societ
concern
would
mitig
approv
nation
level
nation
scienc
advisori
board
biosecur
nsabb
establish
us
govern
deal
gener
biosecur
issu
recent
shakeup
composit
board
appar
move
away
oversight
experi
particularli
gain
function
begley
time
clear
overal
safeti
laboratori
respect
microbiolog
work
excel
may
chang
experi
becom
complex
new
research
enter
field
remain
seen
one
approach
risk
mitig
control
potenti
danger
microb
unit
state
select
agent
program
list
viral
bacteri
toxic
agent
requir
special
effort
oversight
nation
select
agent
registri
nd
list
accompani
rule
draft
time
understand
concern
new
terrorist
attack
follow
event
septemb
natur
list
accompani
rule
highli
controversi
instanc
agent
list
certainli
research
would
agre
kind
addit
oversight
import
list
agent
expand
use
kind
analysi
broad
polici
issu
respect
border
intern
treati
present
interest
complex
polici
issu
exampl
convent
biolog
divers
cbd
nd
treati
relat
biosafeti
broadli
defin
cartagena
protocol
nd
access
benefit
share
nagoya
protocol
nd
plu
technic
assess
process
inform
main
convent
sbstta
nd
may
direct
impact
scientif
research
although
unit
state
parti
convent
import
scientist
understand
basic
convent
work
outsid
nation
border
